Switching from zoledronic acid to denosumab increases the risk for developing medication-related osteonecrosis of the jaw in patients with bone metastases

Purpose Switch from zoledronic acid (ZA) to denosumab may increase the risk of medication-related osteonecrosis of the jaw (MRONJ) owing to the additive effect of denosumab on the jawbone and residual ZA activities. We evaluated the risk of developing MRONJ in patients who received ZA, denosumab, or...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer chemotherapy and pharmacology 2021-06, Vol.87 (6), p.871-877
Hauptverfasser:	Ikesue, Hiroaki, Doi, Kohei, Morimoto, Mayu, Hirabatake, Masaki, Muroi, Nobuyuki, Yamamoto, Shinsuke, Takenobu, Toshihiko, Hashida, Tohru
Format:	Artikel
Sprache:	eng
Schlagworte:	Antiangiogenic agents Antiangiogenics Biomedical materials Cancer Research Confidence intervals Evaluation Jaw Jawbone Medicine Medicine & Public Health Metastases Metastasis Monoclonal antibodies Oncology Osteonecrosis Patients Pharmacology/Toxicology Regression analysis Risk analysis Risk assessment Risk factors Short Communication Statistical analysis Teeth Tooth extractions Zoledronic acid
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!